INTS
Price
$0.28
Change
-$0.01 (-3.45%)
Updated
Aug 29 closing price
Capitalization
13.27M
80 days until earnings call
OABI
Price
$1.60
Change
-$0.04 (-2.44%)
Updated
Aug 29 closing price
Capitalization
230.33M
Interact to see
Advertisement

INTS vs OABI

Header iconINTS vs OABI Comparison
Open Charts INTS vs OABIBanner chart's image
Intensity Therapeutics
Price$0.28
Change-$0.01 (-3.45%)
Volume$4.55M
Capitalization13.27M
OmniAb
Price$1.60
Change-$0.04 (-2.44%)
Volume$165.76K
Capitalization230.33M
INTS vs OABI Comparison Chart in %
Loading...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OABI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INTS vs. OABI commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INTS is a Hold and OABI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (INTS: $0.28 vs. OABI: $1.60)
Brand notoriety: INTS and OABI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INTS: 97% vs. OABI: 32%
Market capitalization -- INTS: $13.27M vs. OABI: $230.33M
INTS [@Biotechnology] is valued at $13.27M. OABI’s [@Biotechnology] market capitalization is $230.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INTS’s FA Score shows that 0 FA rating(s) are green whileOABI’s FA Score has 1 green FA rating(s).

  • INTS’s FA Score: 0 green, 5 red.
  • OABI’s FA Score: 1 green, 4 red.
According to our system of comparison, OABI is a better buy in the long-term than INTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INTS’s TA Score shows that 4 TA indicator(s) are bullish while OABI’s TA Score has 4 bullish TA indicator(s).

  • INTS’s TA Score: 4 bullish, 5 bearish.
  • OABI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, INTS is a better buy in the short-term than OABI.

Price Growth

INTS (@Biotechnology) experienced а -7.27% price change this week, while OABI (@Biotechnology) price change was -13.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

INTS is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OABI($230M) has a higher market cap than INTS($13.3M). OABI YTD gains are higher at: -54.802 vs. INTS (-83.977). INTS has higher annual earnings (EBITDA): -12.56M vs. OABI (-51.78M). OABI has more cash in the bank: 41.6M vs. INTS (2.22M). INTS has less debt than OABI: INTS (125K) vs OABI (21.8M). OABI has higher revenues than INTS: OABI (23M) vs INTS (0).
INTSOABIINTS / OABI
Capitalization13.3M230M6%
EBITDA-12.56M-51.78M24%
Gain YTD-83.977-54.802153%
P/E RatioN/AN/A-
Revenue023M-
Total Cash2.22M41.6M5%
Total Debt125K21.8M1%
TECHNICAL ANALYSIS
Technical Analysis
INTSOABI
RSI
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
58%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
65%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 4 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 10 days ago
70%
Bullish Trend 26 days ago
68%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OABI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PBIGF0.190.02
+8.82%
Paradigm Biopharmaceuticals Ltd.
KKPCF28.09N/A
N/A
Kaken Pharmaceutical Co., Ltd.
FOSUY17.50N/A
N/A
Fosun International, Ltd.
PGPHF1392.91-11.93
-0.85%
Partners Group Holding Zug Namen-Akt
SGGTF0.04-0.01
-13.38%
SIGNATURE RES LTD CDA

INTS and

Correlation & Price change

A.I.dvisor tells us that INTS and ACAD have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and ACAD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-3.09%
ACAD - INTS
28%
Poorly correlated
-0.91%
CCCC - INTS
27%
Poorly correlated
+1.96%
OABI - INTS
25%
Poorly correlated
-2.44%
GPCR - INTS
25%
Poorly correlated
+0.84%
CLGN - INTS
24%
Poorly correlated
-5.42%
More

OABI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OABI has been loosely correlated with BEAM. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OABI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OABI
1D Price
Change %
OABI100%
-2.44%
BEAM - OABI
41%
Loosely correlated
-2.91%
ALEC - OABI
38%
Loosely correlated
-1.67%
RXRX - OABI
38%
Loosely correlated
-3.39%
IMNM - OABI
37%
Loosely correlated
-3.94%
CLDX - OABI
37%
Loosely correlated
-1.34%
More